Loading…
Amazing Meds sold unapproved and misbranded compounded drug products, including retatrutide and semaglutide, through its website in violation of Federal Food, Drug, and Cosmetic Act sections 505(a), 502(f)(1), 301(a), and 301(d), which require FDA approval and proper labeling before marketing drugs. The company's retatrutide products lacked FDA approval as new drugs and failed to bear adequate directions for use, while semaglutide product claims were found to be false or misleading. The enforcement action was based on FDA's August 2025 review of the company's website operations selling these compounded products directly to U.S. consumers over the internet.